Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
12–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A clinical diagnosis of nonsegmental vitiligo with depigmented area including all of the following:
1. ≥ 0.5 F-VASI on the face
2. ≥ 3.0 T-VASI (body areas not including the face)
3. Total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.
Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.
You may not be if
No pigmented hair within any of the vitiligo areas on the face.
Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders.
Used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas.
Previous adverse reaction to NB-UVB phototherapy that caused discontinuation of therapy.
Lack of response (little or no repigmentation) to prior NB-UVB phototherapy.
History of thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, ischemic stroke, myocardial infarction).
Any other skin disease that, in the opinion of the investigator, would interfere with the study cream application or study assessments.
Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chicken pox) within 1 week before baseline.
Any serious illness or medical, physical, or psychiatric condition(s) that pose a significant risk to the participant; or interfere with interpretation of study data.
Recent use of topical or systemic medications (including biologics or JAK inhibitors), or laser or phototherapy to treat vitiligo. Note: Recent may be defined differently for different treatments.
Specific protocol-defined chemistry, hematology, and serological lab values.
Those who are pregnant, lactating or considering pregnancy during the period of study participation.
Clareo Health | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
